Danaher Corporation (DHR)
What changed in recent filings
- Revenue +6% YoYQuarter ended Jun 26, 2026
- Institutions — 11 new · 4 added · 2 reduced13F · as of end of 2026 Q2
- Debt-to-equity 0.3x → 0.5xMar 27, 2026 → Jun 26, 2026
What changed in recent SEC filings — factual, not a buy/sell recommendation.
Institutions holding Danaher Corporation
How many of the institutions we track reported holding this stock, quarter by quarter.
2019 Q1: 3 → 2026 Q2: 17 institutions
Counts the 52 institutions we track that reported holding this stock — their full reported holdings, not just the largest positions. Not the total number of institutional holders in the US. Figures are as of quarter-end and disclosed up to 45 days later. Descriptive only — not investment advice.
Which institutions hold Danaher Corporation
Institutions we track that reported holding this stock in their most recent 13F.
- Dodge & Cox0.03% of portfolio · held as of 2019 Q1 or earlier
- Temasek Holdings (Singapore)0.14% of portfolio · since 2025 Q1
- Third Point LLC2.20% of portfolio · since 2025 Q2
- Glenview Capital Management3.97% of portfolio · since 2025 Q2
- Bridgewater Associates0.02% of portfolio · since 2025 Q4
- Tudor Investment Corp0.03% of portfolio · since 2026 Q1
- Point72 Asset ManagementNew this quarterunder 0.01% of portfolio · since 2026 Q2
- Moore Capital ManagementNew this quarter0.05% of portfolio · since 2026 Q2
- Duquesne Family OfficeNew this quarter0.18% of portfolio · since 2026 Q2
- Caisse de depot (Quebec)0.09% of portfolio · held as of 2026 Q2 or earlier
- Tiger Global ManagementNew this quarter0.36% of portfolio · since 2026 Q2
- National Pension Service (Korea)0.18% of portfolio · held as of 2026 Q2 or earlier
- Generation Investment Management12.52% of portfolio · held as of 2026 Q2 or earlier
- PRIMECAP Management0.21% of portfolio · held as of 2026 Q2 or earlier
- Harris Associates (Oakmark)under 0.01% of portfolio · held as of 2026 Q2 or earlier
- Gates Foundation Trust0.21% of portfolio · held as of 2026 Q2 or earlier
- Baillie Gifford & CoNew this quarterunder 0.01% of portfolio · since 2026 Q2
Based on 13F filings — quarter-end holdings, disclosed up to 45 days later. Holding a stock is a fact we report, not a recommendation to buy or sell.
Company overview
Danaher. A life-sciences and diagnostics conglomerate. It has achieved compounding growth via a high-margin consumables business and continuous acquisitions.
What is the Biotech & Health sector?
Pharma, biotech, and medical devices. Driven by trial-result events.
Danaher Corporation is classified under the Biotech & Health sector. See peers below.
Danaher Corporation key financials
Based on SEC filings · as of Jun 26, 2026
Tap a metric name to see its meaning in the glossary.
Danaher Corporation vs Biotech & Health sector benchmark
Median of 35 representative sector stocks · SEC filings · factual comparison (not advice)
A simple comparison to the sector benchmark. Higher or lower doesn’t mean good/bad or buy/sell.
DHR revenue by segment summary
SEC 10-Q · segment totals cross-checked against total revenue
2026-06-26 revenue was $6.3B, +5.5% YoY.
The largest segment is Diagnostics, 39.4% of revenue — a relatively diversified structure.
Recent revenue growth was led mainly by the Diagnostics segment (about 48% of the increase).
Full segment weights, YoY changes, and an AI synthesis are available in the detailed analysis.
ETFs holding Danaher Corporation
Per SEC N-PORT · 2026-06-30 · by weight · factual
DHR on Stocklore
- Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
- Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
- 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
- Sector-relative metrics — Valuation and growth compared with the Biotech & Health average
Peers · Biotech & Health
DHR FAQ
What is Danaher Corporation (DHR)?
Danaher. A life-sciences and diagnostics conglomerate. It has achieved compounding growth via a high-margin consumables business and continuous acquisitions.
What sector is Danaher Corporation in?
Danaher Corporation is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.
What are Danaher Corporation's key financials?
As of Jun 26, 2026 in SEC filings: Revenue growth (YoY) 4.6%, Operating margin 18.0%, Net margin 15.9%, ROE 6.9%, Debt-to-equity 0.51x. Definitions and interpretation are available on Stocklore.
What are Danaher Corporation's main revenue segments?
The largest segment is Diagnostics, about 39.4% of revenue. Segment totals are cross-checked against total revenue from SEC filings.
Where can I analyze Danaher Corporation (DHR) stock?
On Stocklore you can see DHR's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.
Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, as of quarter-end), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.